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Abstract
Objective The Suspicion Index (SI) screening tool was de-
veloped to identify patients suspected of having Niemann-
Pick disease type C (NP-C). The SI provides a risk prediction
score (RPS) based on NP-C manifestations within and across
domains (visceral, neurological, and psychiatric). The aim of
these subanalyses was to further examine the discriminatory
power of the SI by age and manifestation–associations by
NP-C suspicion-level and leading manifestations.
Methods The original retrospectively collected data were split
into three patient age groups, where NP-C-positive cases were
>16 years (n=30), 4–16 years (n=18), and <4 years (n=23),
and patients’ RPS were analyzed by logistic regression. Co-
occurrence of manifestations within groups of suspicion level
(low, medium, high) and leading manifestations (presence/
absence of ataxia, cognitive decline, psychosis, and spleno-
megaly) were analyzed descriptively.
Results NP-C-positive cases versus controls showed strong
discriminatory power of RPS. Area under the receiver oper-
ating characteristic curve was 0.964 (>16 years) and 0.981
(4–16 years) but weaker 0.562 for infants (<4 years). Patients
with RPS <70 were characterized by a lack of psychiatric
manifestations and low levels of neurological involvement,
suggestive of a preneurological phase of the disease. In pa-
tients >4 years, prominent leading manifestation–associations
were ataxia with dystonia, dysarthria/dysphagia, and cognitive
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decline. Psychosis was associated with dysarthria/dysphagia
but also with cognitive decline and treatment-resistant psychi-
atric symptoms.
Conclusions The SI tool maintains strong discriminatory
power in patients >4 years but is not as useful for infants
<4 years. The SI is also informative regarding the association
and co-occurrence of manifestations in patients with NP-C.
Introduction
Niemann-Pick disease type C (NP-C) is a rare, autosomal
recessive disease caused by mutations in the NPC1 (95 % of
cases) or NPC2 genes. The disease is characterized by het-
erogeneous and oligosymptomatic presentation of visceral,
neurological, and psychiatric manifestations, making for dif-
ficult and often delayed diagnosis (Patterson et al. 2012;
Vanier 2010; Wraith et al. 2009; Wraith and Imrie 2009).
Current estimated incidence is 0.85 per 100,000 live births
(Orphanet Report Series 2011).
Diagnosis of NP-C is made via physical assessment of the
patient, biochemical tests involving filipin staining of skin
fibroblasts, and genetic sequencing of the NPC1 and NPC2
mutations (Wraith et al. 2009; Vanier 2010; Patterson et al.
2012). Filipin staining and genetic analysis are recommended
as the first-line diagnostic tests, to be carried out in parallel if
possible in order to obtain complementary information
(Patterson et al. 2012). However, the choice of first-line test
depends on the local availability of techniques and expertise.
Miglustat, the first and currently only specific treatment
for pediatric and adult patients with NP-C, was approved for
use in the European Union in 2009 (Zavesca®, Actelion
Pharmaceuticals Ltd, Allschwil, Switzerland) (European
Medicines Agency 2012; Patterson et al. 2012) and in
Japan in April 2012 (Brazaves®). Early diagnosis of NP-C
is essential so that uninterrupted miglustat therapy can start
at the onset of neurological manifestations (Wraith et al.
2010; Wraith et al. 2009; Pineda et al. 2010; Vanier 2010;
Wraith and Imrie 2009; Chien et al. 2012).
The NP-C Suspicion Index (SI) screening tool, devel-
oped by an international panel of NP-C clinical experts,
aids physicians unfamiliar with NP-C in early identification
of patients with suspicion of NP-C (www.NPC-SI.com;
Wijburg et al. 2012). A risk prediction score (RPS) is
calculated by the presence of key clinical manifestations
of NP-C within and across three domains plus family his-
tory information. Due to the disease variability at age of
onset and presentation, it is important to determine whether
the SI tool performs in different patient groups. This man-
uscript reports subanalyses of the original study data to
investigate the discriminatory power of the SI tool by age
and to investigate associations by the presence and absence
of four leading NP-C manifestations.
Methods
Subanalyses were performed on data arising from a pub-
lished study reporting the development of the NP-C SI
tool (Wijburg et al. 2012). The published study involved
a retrospective chart review of 216 patients in seven
specialist NP-C centers in Europe and Australia. Data
were collected from two patient groups who were tested
for NP-C: 71 NP-C-positive cases, confirmed by classical
or variant NP-C filipin staining, with subsequent identi-
fication of at least one mutation in NPC1 or NPC2
genes; and 64 suspected NP-C cases but in whom filipin
staining was negative. Data for NP-C-positive cases and
suspected cases were collected up to the decision to refer
for a filipin test. Data were also collected from 81
control patients who were without suspicion for NP-C
but who presented with at least one symptom associated
with NP-C and, where possible, from the same outpatient
clinic as the NP-C-positive and suspected cases.
Collected data included demographics such as age and
gender, presence of individual manifestations within the
three domains (visceral, neurological, and psychiatric), and
patient’s first- or second-degree family history. The scoring
system of the SI tool assigned points to individual NP-C
manifestations within each domain. In addition, points were
assigned for manifestations presenting across two or three
domains and for familial history. The sum of all points gave
the total RPS for each patient. RPS ≥70 indicated high
suspicion of NP-C and recommendation for immediate test-
ing at an NP-C specialist center. RPS score between 40 and
69 indicated moderate suspicion for NP-C and recommen-
dation for follow-up observation as well as further discussion
with an NP-C referral center. RPS <40 indicated a low
probability of NP-C.
Subanalyses involved categorization of all patients by
age: infantile patients<4 years (n=23 for NP-C-positive
patients, n=23 for NP-C-suspected cases, and n=7 for con-
trol patients), juvenile patients 4–16 years (n=18 for NP-C-
positive patients, n=16 for NP-C-suspected patients, and
n=39 for control patients), and adolescent patients >16 years
(n=30 for NP-C-positive patients, n=25 for NP-C-suspected
patients, and n=35 for control patients). Frequency distribu-
tion of manifestations within and across domains was tabu-
lated for each patient age group. The performance of the total
and individual RPS for each domain was investigated via
logistic regression within each age group using the outcome
NP-C-positive cases versus combined NP-C-suspected cases
and controls as binary dependent variables and the RPS as an
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independent variable. Receiver operating characteristic
(ROC) curve (sensitivity versus 1-specificity) analysis was
performed, and the area under the curve (AUC) was estimat-
ed. Frequency distribution of manifestations by RPS (disease
severity) categories<70 points, 70–150 points, and >150
points was tabulated and also presented graphically to show
the scatter of RPS by age, where age was transformed to a
logarithmic scale to improve visual assessment in the infan-
tile group.
Association (co-occurrence) of manifestations by the pres-
ence and absence of four leadingNP-Cmanifestations—ataxia,
cognitive decline, psychosis, and splenomegaly—were exam-
ined descriptively by frequency distribution of manifestations
and graphical presentation in patients >4 years. These leading
manifestations are moderate or strong indicators for NP-C in
each domain, and due to their high frequency of occurrence, the
presence of one or more of these manifestations is most often
the reason for referral for NP-C testing. Other specific NP-C
symptoms, such as vertical supranuclear gaze palsy (VSGP),
cataplexy, and epilepsy, were excluded as leading symptoms
because their presence is rarely the initial cause for referral for
NP-C testing due to their lower frequency, generally later onset,
and—in some cases such as VSGP—difficulty of diagnosis.
These data were analyzed descriptively.
Results
Frequency and association of manifestations by age group
The most frequent (>50 %) manifestations displayed in in-
fantile patients (<4 years of age) were prolonged neonatal
jaundice, splenomegaly, and delayed developmental mile-
stones. Hypotonia occurred mainly in infantile patients but
not in older patients. Infantile patients demonstrated low
levels of psychiatric manifestations and reduced levels of
neurological involvement. The majority of manifestations
in this patient group appeared across the visceral and neuro-
logical domains (Fig. 1).
Visceral manifestations were less frequent in adolescent
patients (>16 years of age), as shown in Fig. 1; however,
findings within the neurological domain, in particular, VSGP,
dystonia, and dysarthria/dysphagia, becamemore frequent. The
frequency of cognitive decline, a strong psychiatric indicator of
NP-C, noticeably increased in juvenile and adolescent patients.
The frequency of other manifestations within the psychiatric
domain, including psychotic symptoms, treatment-resistant
psychiatric symptoms, disruptive or aggressive behavior, and
other psychiatric disorders also increased in patients >16 years
of age. As in the infantile patient group, juvenile and adolescent
Fig. 1 Individual
manifestation–association in
each domain by age group.
Frequency (%) of positive
Niemann-Pick disease type C
(NP-C) manifestations in each
of three domains (visceral,
neurological, and psychiatric) at
each age group (infantile
<4 years, juvenile 4–16 years,
and adolescent >16 years)
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patients displayed manifestations clustered across the visceral
and neurological domains. Additionally, patients >4 years of
age displayed an increased frequency of combined manifesta-
tions across the visceral/psychiatric, visceral/neurological, and
neurological/psychiatric domains.
Frequency and association of manifestations by RPS
Patients with a total RPS <70 points demonstrated a noticeable
lack of psychiatric findings and lower levels of neurological
involvement, indicating a more visceral phenotype (Fig. 2).
Increased presence of VSGP, splenomegaly, ataxia, and
all psychiatric manifestations were associated with high
suspicion of NP-C (RPS >150 points). Increased frequen-
cy of manifestations both within the same category, but
more so across categories, greatly increased the RPS. The
mean RPS for infantile patients <4 years of age was
much lower than RPS for juvenile and adolescent pa-
tients (mean RPS of 79.2 points compared with 190 and
179, respectively, Fig. 3). As shown in Fig. 4, patients
with an RPS score of <70 tended to be infantile patients
<4 years of age.
Fig. 2 Individual
manifestation–association in
each domain by total risk
prediction score (RPS).
Frequency (%) of positive
Niemann-Pick disease type C
(NP-C) manifestations in each
of the three domains (visceral,
neurological, and psychiatric) at
each RPS level (<70 points, 70–
150 points, and >150 points)
Fig. 3 Mean total risk
prediction score (RPS) by age
and scoring for individual and
combined domains. Mean total
RPS for each age category and
the score for manifestations
within individual and combined
domains
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Association by presence/absence of leading manifestations
in patients >4 years
The leading neurological manifestation of ataxia (n=41, 85.4 %
of patients), a moderate indicator of NP-C according to the SI
tool, most commonly occurred with other manifestations within
the same category, such as dystonia and dysarthria/dysphagia,
but also with cognitive decline, which is a psychiatric domain
manifestation (Fig. 5). The two leading psychiatric manifesta-
tions were cognitive decline (a strong indicator of NP-C) and
psychosis (a moderate indicator of NP-C). NP-C-positive pa-
tients showing manifestations of cognitive decline (n=42,
87.5 %) displayed increased levels of psychosis and slightly
elevated frequency of treatment-resistant psychiatric symptoms,
which are within the same domain category. However, cross-
domain manifestations in the neurological category were also
Fig. 4 Total risk prediction
score (RPS) versus age (years)
for Niemann-Pick disease type
C (NP-C)-positive cases. Total
RPS and age for each NP-C-
positive case (<4 years n=23,
4–16 years n=18, >16 years
n=30)
Fig. 5 Manifestation–
association in patients ≥4 years
with Niemann-Pick disease type
C (NP-C) by presence/absence
of ataxia and cognitive decline.
Frequency (%) of positive NP-C
manifestations in each of three
domains (visceral, neurological,
and psychiatric) associated with
and without ataxia and with and
without cognitive decline
(n=48)
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observed. These symptoms include ataxia, gelastic cataplexia,
dystonia, and seizures (Fig. 5). Patients without cognitive de-
cline showed increased findings of other types of psychiatric
disorders. Psychosis (n=15, 31.3 %) was associated with other
illness features, including treatment-resistant psychiatric symp-
toms and across-category neurological findings, including
dysarthria/dysphagia and dystonia (Fig. 6).
The leading manifestation in the visceral domain was
splenomegaly (n=26, 54.2 %), a strong indicator of NP-C.
There was little difference between manifestation–association
within and across domains for patients with or without spleno-
megaly (Fig. 6). Patients without splenomegaly (n=22)
showed a slight increase in frequency of prolonged neonatal
jaundice, ataxia, and dysarthria/dysphagia compared with pa-
tients with splenomegaly.
Discriminatory power by age
Discriminatory power of the NP-C SI for NP-C-positive
cases versus combined NP-C-suspected cases and controls
was stronger for juvenile (aged 4–16 years) and adolescent
(>16 years of age) patients than for infantile (<4 years of age)
patients. The estimated ROC AUC values were 0.981 and
0.964, respectively (Fig. 7). The domain with highest dis-
criminatory power for NP-C in these age groups was the
neurological domain, with ROC AUC values of 0.994 (4–
16 years) and 0.873 (>16 years), respectively. The weakest
individual domain was the visceral category. The discrimi-
natory performance of the NP-C SI in infantile patients
(<4 years of age) was poor, with ROC AUC value of 0.562
for the total RPS, with related poor performance in all three
individual domains (visceral AUC = 0.597, neurological
AUC = 0.615, and psychiatric AUC = 0.501).
Discussion
This study was carried out to further determine the association
of manifestations and the discriminatory power of the SI in
different age groups of patients with NP-C. Infantile patients
displayed frequent manifestations of prolonged neonatal jaun-
dice, splenomegaly, and delayed developmental milestones.
This was as expected due to these signs being highly character-
istic of NP-C in this age group (Vanier 2010). Infants <4 years
of age also demonstrated fewer cross-domain manifestations
compared with juvenile and adolescent patients, particularly
the near absence of psychiatric manifestations. VSGP and
gelastic cataplexia are the two strongest neurological indicators
for NP-C according to the SI tool. These manifestations are
usually present in low frequencies in infantile patients, if found
at all. If VSGP is present, it may not be recognized, and the
presence of gelastic cataplexia usually appears during the late
Fig. 6 Manifestation–
association in patients ≥4 years
with Niemann-Pick disease type
C (NP-C) by presence/absence
of psychosis and splenomegaly.
Frequency (%) of positive NP-C
manifestations in each of the
three domains (visceral,
neurological, and psychiatric)
associated with and without
psychosis and with and without
splenomegaly (n=48)
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infantile period (>3 years of age) (Patterson et al. 2012; Vanier
2010). Common neurological manifestations in infantile
patients <4 years of age can include delays in developmen-
tal motor milestones, hypotonia, and language/speech delay
(Vanier 2010; Patterson et al. 2012).
Whereas visceral manifestations appeared less frequently
in adolescent patients (>16 years of age) with NP-C, neuro-
logical manifestations, including VSGP, dystonia, and
dysarthria/dysphagia, showed an increased frequency com-
pared with infant and juvenile patients. Epilepsy was the
only manifestation to decrease in frequency between juve-
nile and adolescent patients. This could be an indicator of
illness severity; mild, slowly progressive cases with less
frequent or severe epilepsy may survive into adolescence
and adulthood, whereas severe cases die during childhood.
Co-occurrence of manifestations both within and across
domains greatly increases the suspicion level of NP-C, as
evidenced by a high total RPS. Cross-domain manifestations
in all three domains were experienced in higher proportions in
patients >4 years of age than in infantile patients <4 years of
age. Manifestations found across the visceral/psychiatric
and visceral/neurological domains were the strongest in-
dicators of NP-C, resulting in a higher point score within
the NP-C SI tool than manifestations found across the
neurological/psychiatric domains. The frequency of mani-
festations within the neurological/psychiatric domains in-
creased in juvenile and adolescent patients, most notice-
ably, cognitive decline and ataxia.
The NP-C SI tool had strong discriminatory power (high
ROC AUC) within and across the three separate domains for
patients aged 4–16 years (juvenile) and>16 years of age
(adolescent) for NP-C-positive cases versus combined NP-C-
suspected cases and controls, confirming the RPS 70 points
suspicion threshold identified in the previously published study
(Wijburg et al. 2012). The SI tool is less able to discriminate
NP-C in infants <4 years of age. This could be due to an inability
to detect specific neurological manifestations and the lack of
development of psychiatric manifestations in this age group. The
Fig. 7 Receiver operating characteristic (ROC) curves. Niemann-Pick
disease type C (NP-C)-positive versus combined NP-C-suspected cases
and controls by age. ROC curves that show higher sensitivity and
specificity for NP-C-positive cases versus combined NP-C-suspected
cases and controls in age groups 4–16 years (juvenile) and >16 years
(adolescent) compared with infantile patients (<4 years). AUC area
under the curve
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individual domain with the weakest ROCAUC value in this age
group was the visceral domain. There is a need to develop an SI
that is well suited to infantile patients. Protocol development is
currently underway to collect more data for infantile patients
with NP-C in order to develop a pediatric-specific SI tool.
Discrimination between specific (e.g., VSGP, cataplexy)
and sensitive (e.g., ataxia, icterus prolonganus, cognitive de-
cline) symptoms as strong indicators of NP-C, as well as the
likelihood of any given symptom co-occurring with symptoms
from other domains, was built into the NP-C SI tool during its
initial construction when the individual RPS of each individual
symptom was calculated and validated (Wijburg et al. 2012).
Multivariable analysis of the SI tool to examine relationships
between individual manifestations within categories was not
possible due to insufficient data (occurrence of zero frequen-
cies) for several binary predictors.
Other types of disease can present with similar visceral,
neurological, and psychiatric manifestations to that of
NP-C. Acid-sphingomyelinase-deficient Niemann-Pick dis-
ease, Sandhoff disease, and Gaucher disease type 3 can all
present with visceral manifestations of hepatosplenomegaly/
splenomegaly and neurological signs including ataxia and
seizures. Patients with Huntington’s disease or progressive
supranuclear gaze palsy can display neurological manifesta-
tions, including dystonia, VSGP, psychiatric symptoms, and
cognitive decline (Patterson et al. 2012). However, suspicion
for NP-C should be greatly increased when patients present
clinical manifestations not only within, but more importantly
across, multiple domains. Therefore, analysis of manifesta-
tions–association based on the SI tool concentrated on the
complexity of manifestations across, rather than within, each
domain. The NP-C SI tool is designed to allow physicians to
objectively assess the likelihood of NP-C in undiagnosed pa-
tients. As such, it is not, and should not be, used as a differential
diagnosis tool. It is possible that patients with other neurolog-
ical disorders may score high on the NP-C SI (e.g. Alzheimer’s
disease patients), but the precise diagnosis of these patients
should be confirmed by further routine testing; it is also
expected that incorrect diagnoses will become less common
as physicians gain more experience using the SI tool.
Study strengths and limitations
A strength of the original published study, and therefore of
these subanalyses, is that control cases were selected from
the same outpatient clinics, where possible, as the NP-C-
positive cases and suspected cases. This arguably increases
the validity of the tool in routine clinical practice.
One notable limitation is the retrospective data being col-
lected from a small group of NP-C-positive infantile patients
(<4 years of age, n=23). As NP-C is a rare disease, it is
difficult for investigators to incorporate sufficient numbers
of patients in studies, thereby making meaningful analysis a
challenge. The current SI tool categorizes delayed develop-
mental milestones in the ancillary category (allocated one
point); however, this manifestation could be a stronger indi-
cator of NP-C for this age group.
The SI tool can only be as good as the quality of patient
data captured in the original study. This does not include
patients who were never detected due to the atypical or
nonspecific presentation of manifestations. As the disease
is progressive, changing from visceral to neuropsychiatric in
nature, the cross-sectional, retrospective nature of the data
set makes it difficult to assess the usefulness of the SI in
aiding early detection and predicting progression of NP-C in
these patients. Further retrospective and future prospective,
longitudinal studies may help to determine how useful the
NP-C SI tool is in clinical practice and also to refine its use.
Conclusions
The NP-C SI tool is useful for providing information regard-
ing association of manifestations within and across visceral,
neurological, and psychiatric domains in infantile, juvenile,
and adolescent patients with NP-C. The screening tool pro-
vides strong predictive power for suspicion of NP-C in
patients >4 years of age but it is not as useful for infantile
patients <4 years of age.
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